financetom
Business
financetom
/
Business
/
Boeing taps debt market to raise $10 billion: sources
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Boeing taps debt market to raise $10 billion: sources
Apr 29, 2024 9:50 AM

April 29 (Reuters) - Boeing ( BA ) on Monday tapped debt

markets to raise $10 billion, after the U.S. planemaker burned

$3.93 billion in free cash during the first quarter following

slowing production of its best-selling jet, sources familiar

with the matter said.

Boeing's ( BA ) credit rating hovered above "junk" status last week

from rating agencies as the planemaker tries to recover from a

crisis that began in January after a midair blowout of a cabin

panel door plug on a nearly new 737 MAX 9.

Investors and analysts have said Boeing ( BA ) could tap bond

markets to get ahead of more than $12 billion in combined debt

coming due in 2025 and 2026.

Credit rating agencies on Monday both assigned ratings

nearing junk to Boeing's ( BA ) new senior unsecured notes, with S&P

assigning a BBB- rating and Moody's assigning a Baa3 rating.

Moody's said the rating reflects Boeing's ( BA ) still-strong

business profile, which continues to mitigate ongoing weak

performance in commercial aircraft, although headwinds

surrounding the division could persist through 2026.

Boeing ( BA ) will use the bond proceeds to increase its liquidity

ahead of maturities on its existing debt load, including $4.3

billion in 2025, S&P wrote on Monday.

"It looks like it will go well," said one of the sources,

who was looking at buying the bonds, adding that he was told it

was eight times oversubscribed.

The deal's bookrunners leading the bond sale include Bank

of America, Citi, JPMorgan and Wells Fargo, according to the

deal's term sheet.

Boeing ( BA ) declined to comment, but pointed to remarks from

Chief Financial Officer Brian West during the company's earnings

last week in which he said Boeing ( BA ) was committed to managing its

balance sheet in a prudent manner, with the goal of prioritizing

its investment-grade rating and helping the factory and supply

chain to stabilize.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Teekay Launches $40 Million Buyback Program
Teekay Launches $40 Million Buyback Program
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Teekay ( TK ) said Monday that its board has authorized a new share buyback program for the repurchase of up to $40 million common stock. The shipping company said it has nearly completed a previous $25 million repurchase program initiated in August 2022, buying back about 3.3 million shares at an average...
Top Premarket Gainers
Top Premarket Gainers
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Intelligent Bio Solutions ( INBS ) shares surged more than 68% pre-bell Monday, extending Friday's rally. Summit Therapeutics ( SMMT ) shares advanced more than 31% after the company reported that a phase 3 trial of ivonescimab demonstrated significantly improved progression-free survival in patients with non-small cell lung cancer. Terns Pharmaceuticals ( TERN...
Top Premarket Decliners
Top Premarket Decliners
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Wheeler REIT (WHLR) shares slumped 23% pre-bell Monday, paring Friday's rally. C4 Therapeutics ( CCCC ) shares dropped 17%, adding to a 7.4% loss in the previous session. SmartKem ( SMTK ) shares were down 11%, reversing from Friday's gains. Price: 7.89, Change: -2.36, Percent Change: -23.02 ...
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Sep 9, 2024
Sunday, Summit Therapeutics Inc. ( SMMT ) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc. The data was presented at the International Association for the Study of Lung Cancer’s 2024 World Conference on Lung Cancer. The trial evaluated monotherapy ivonescimab against monotherapy Merck ( MRK...
Copyright 2023-2026 - www.financetom.com All Rights Reserved